Generate Biomedicines (NASDAQ:GENB) Now Covered by Analysts at Piper Sandler

Analysts at Piper Sandler began coverage on shares of Generate Biomedicines (NASDAQ:GENB) in a research report issued to clients and investors on Tuesday. The firm set an “overweight” rating and a $24.00 price target on the stock. Piper Sandler’s target price would indicate a potential upside of 91.69% from the company’s current price.

Other equities research analysts also recently issued reports about the company. Guggenheim began coverage on Generate Biomedicines in a report on Tuesday. They issued a “buy” rating and a $30.00 price objective for the company. Cantor Fitzgerald initiated coverage on shares of Generate Biomedicines in a research report on Tuesday. They issued an “overweight” rating for the company. Morgan Stanley assumed coverage on shares of Generate Biomedicines in a research note on Tuesday. They set an “overweight” rating and a $20.00 price target for the company. Wall Street Zen raised shares of Generate Biomedicines to a “hold” rating in a research report on Saturday, March 14th. Finally, The Goldman Sachs Group assumed coverage on shares of Generate Biomedicines in a report on Tuesday. They issued a “buy” rating and a $26.00 target price for the company. Five equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $25.00.

Generate Biomedicines Price Performance

NASDAQ:GENB opened at $12.52 on Tuesday. Generate Biomedicines has a 52-week low of $11.00 and a 52-week high of $15.32.

Generate Biomedicines Company Profile

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.